Eye Allergy Relief

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Eye Allergy Relief
Generic name
PHENIRAMINE MALEATE AND NAPHAZOLINE HYDROCHLORIDE
Manufacturer
Target Corporation
Product type
HUMAN OTC DRUG
SPL set ID
806ad1b6-0de7-4e9a-be86-475c0ef2c340
SPL ID
316ecb95-254a-e9ab-e063-6294a90a7509
Version
10
Effective date
2025-03-28
Source export date
2026-10-27
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-27/b7a5e61d87a3b8f87f4c3ff7b526bfbf6baf84c840f565574c7d83d4083e2b38/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
6be3667a3beefe6c0ead4c723ea963050533a2bc725a8044d58b07d18b258c55
Import run
20261027T193451Z
Imported at
2026-10-27 20:48:01
Harmonized routes table
Harmonized routes
OPHTHALMIC

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings For external use only Do not use if you are sensitive to any ingredient in this product if solution changes color or becomes cloudy Ask a doctor before use if you have heart disease high blood pressure trouble urinating due to an enlarged prostate gland narrow angle glaucoma When using this product overuse may cause more eye redness pupils may become enlarged temporarily do not touch tip of container to any surface to avoid contamination you may feel a brief tingling after putting drops in eye replace cap after use remove contact lenses before using Stop use and ask a doctor if you experience eye pain changes in vision redness or irritation of the eye that worsens or lasts more than 72 hours Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Accidental oral ingestion in infants and children may lead to coma and marked reduction in body temperature.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.